Matches in Nanopublications for { ?s ?p "[We report data from a phase I/II, multicenter, open-label study of Korean patients with refractory KRAS wild-type adenocarcinoma NSCLC (defined as patients with evidence of disease progression during or within 6 months of treatment with chemotherapy and gefitinib or erlotinib).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- assertion description "[We report data from a phase I/II, multicenter, open-label study of Korean patients with refractory KRAS wild-type adenocarcinoma NSCLC (defined as patients with evidence of disease progression during or within 6 months of treatment with chemotherapy and gefitinib or erlotinib).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_assertion description "[We report data from a phase I/II, multicenter, open-label study of Korean patients with refractory KRAS wild-type adenocarcinoma NSCLC (defined as patients with evidence of disease progression during or within 6 months of treatment with chemotherapy and gefitinib or erlotinib).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_provenance.